Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
HIGH POINT, N.C. , March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study
View HTML
Toggle Summary vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
HIGH POINT, N.C. , March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal HIGH POINT, N.C. , Feb.
View HTML
Toggle Summary vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c HIGH POINT, N.C. , Feb. 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company
View HTML
Toggle Summary vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim , Newsoara Biopharma, has initiated a phase 2 study in COPD in China HIGH POINT, N.C. , Feb.
View HTML
Toggle Summary vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
HIGH POINT, N.C. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
HIGH POINT, N.C. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as
View HTML
Toggle Summary vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
HIGH POINT, N.C. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971.
View HTML
Toggle Summary vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
HIGH POINT, N.C. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 million with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago -based institutional investor.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Third Quarter Financial Results and Update
HIGH POINT, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020 , and provided an update on the progress of its clinical programs. “Following our decision to conclude enrollment in the Elevage
View HTML